Company news
Compugen Ltd. news in 2020
Compugen Ltd.'s news releases, calls and decks from 2020, newest first.
Compugen Announces First Development Milestone in License Agreement with AstraZeneca for the Development of Bispecific and Multi-specific Antibody Products
December 22, 2020
Compugen Reports Third Quarter 2020 Results
November 4, 2020
Compugen Further Expands Patent Portfolio for TIGIT Inhibitor COM902 with Composition of Matter Patent in China
November 1, 2020
Compugen Presents New Research Data Further Supporting PVRIG as a Potentially Promising Target for Cancer Immunotherapy
October 26, 2020
Compugen to Release Third Quarter 2020 Results on Thursday, November 5, 2020
October 21, 2020
Compugen Announces Addition of Immuno-oncology Pioneer Dr. Nils Lonberg to its Scientific Advisory Board
September 29, 2020
Compugen Doses First Patient in Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® and Anti-TIGIT Antibody
September 7, 2020
Compugen to Present at Upcoming September 2020 Investor Conferences
September 2, 2020
Compugen Expands Patent Portfolio for TIGIT Inhibitor COM902 with New US Composition of Matter Patent
August 27, 2020
Compugen Reports Second Quarter 2020 Results
July 29, 2020
Compugen to Release Second Quarter 2020 Results on Thursday, July 30, 2020
July 15, 2020
Compugen Announces Appointment of Dr. Oliver Froescheis as Senior Vice President, Corporate and Business Development
January 7, 2020
Decks in 2020
- Technical Presentation (April 2020)
Technical · 24 slides · Apr 27, 2020